High-Pressure Bail-out Coronary Stenting Without Anticoagulation: Early Outcome and Follow-up Results

Witkowski1, Chmielak, Dabrowski

  • 1Hemodynamics Department, Institute of Cardiology, 42 Alpejska St., 04-628, Warsaw, Poland. witkowski@hbz.com.pl

Insights

High-pressure bail-out coronary stenting using only antiplatelet therapy is effective for complicated percutaneous transluminal coronary angioplasty (PTCA). While restenosis rates are high, re-PTCA successfully treats most cases, with 60% of patients remaining event-free at one year.

Area of Science:

  • Interventional Cardiology
  • Cardiovascular Research
  • Medical Device Technology

Background:

  • Percutaneous transluminal coronary angioplasty (PTCA) complications sometimes necessitate bail-out stenting.
  • Optimal antithrombotic strategies post-stenting, especially without anticoagulation, require evaluation.

Purpose of the Study:

  • To assess the immediate and long-term outcomes of high-pressure bail-out coronary stenting.
  • To evaluate the efficacy and safety of using only antiplatelet therapy post-procedure.

Main Methods:

  • 32 patients with complicated PTCA underwent bail-out stenting (54 stents) at high pressure (mean 15.5 mmHg).
  • Post-procedure treatment included ticlopidine and aspirin only; no anticoagulation was administered.
  • Outcomes assessed included procedural success, in-hospital events, and one-year major adverse cardiac events (MACE).

Main Results:

  • Successful stent delivery in all patients; 96.9% procedural success.
  • One acute stent thrombosis (3.1%) requiring bypass surgery (CABG); 12.5% non-Q wave myocardial infarctions.
  • At six months, 46.4% restenosis rate, with 9/13 successfully treated by re-PTCA. At one year, 40.6% MACE, including target lesion revascularization in 34.4%.

Conclusions:

  • High-pressure bail-out coronary stenting with an antiplatelet regimen is effective and safe for complicated PTCA.
  • Despite a high restenosis rate, in-stent restenosis is often manageable with repeat PTCA.
  • Approximately 60% of patients experienced an uneventful clinical course at one year.